Actuate Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for elraglusib...
Read more
Tempus announced a brand-new multi-omics collaboration with Actuate Therapeutics to support its ongoing Phase 1/2 Study of elraglusib, formerly...
Read more
Actuate Therapeutics and The University of Kansas Cancer Center announced the enrollment of the first patient on a Phase...
Read more
Actuate Therapeutics, Inc. announced that their Phase 2 open-label single arm study of elraglusib (9-ING-41) plus gemcitabine/nab-paclitaxel treatment met...
Read more
Actuate Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for 9-ING-41 for...
Read more
Actuate Therapeutics, Inc. announced enrollment of the first patients with first-line advanced pancreatic cancer in a phase 2 study...
Read more
Actuate Therapeutics, Inc. has raised an additional $6.5M in a Series B-3 financing round led by Bios Partners with...
Read more
We are delighted to announce that Actuate Therapeutics is the latest company to join the Kairos portfolio. Founded in...
Read more